The American Academy of Dermatology acne guideline abstract names benzoyl peroxide, topical retinoids, topical antibiotics and oral doxycycline among its strong recommendations, and other sources describe retinol, adapalene, tazarotene and oral isotretinoin. This guide reports what each source says, including any regulatory wording. It does not rank the options or say which one suits a person.
What the acne guideline abstract says
The guideline abstract says strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. The abstract does not name tretinoin or any strength. The guideline's conflict-of-interest statement says one author serves as an advisory board member for Ortho Dermatologics, receiving honoraria.
Topical options in the sources
| Question | What the source says |
|---|---|
| Retinol serum compared with tretinoin cream? | A 12-week double-blind trial in photoaged women compared retinol serum with tretinoin cream in escalating doses (retinol 0.25%, 0.5%, 1.0% and tretinoin 0.025%, 0.05%, 0.1%, per the abstract's methods). Both demonstrated parity across investigator and subject assessment measurements as well as diagnostic measures including TEWL (the abstract's abbreviation). |
| Retinol 0.075% cream? | A randomized, blinded, vehicle-controlled study over 26 weeks (per the abstract) reported that three of the 57 subjects withdrew due to irritation, a rate much smaller than that noted in the authors' previous study with topical tretinoin. The tretinoin strength in that earlier study is not given here. |
| Benzoyl peroxide (BPO) compared with adapalene? | A Cochrane review concluded that BPO as monotherapy or add-on treatment may be more effective than placebo or no treatment for improving acne, and that there may be little to no difference between BPO and either adapalene or clindamycin. It also reported that risk of treatment discontinuation may be higher with BPO than with placebo or no treatment (RR 2.13, 95% CI 1.55 to 2.93; 24 RCTs; 13,744 participants; treatment for 10 to 12 weeks; low-certainty evidence). The most common causes of withdrawal were erythema, pruritus, and skin burning. |
| Adapalene with BPO? | A systematic review and network meta-analysis of topical acne treatments concluded that adapalene in combination with BPO may be the most effective treatment for acne but with a slightly higher incidence of withdrawal than monotherapy. Adapalene strengths are not given in the text used here. |
Tazarotene and a tretinoin and benzoyl peroxide cream
The Tazorac (tazarotene) cream label lists embryofetal toxicity and says: "TAZORAC Cream contains tazarotene, which is a teratogenic substance. TAZORAC Cream is contraindicated in pregnancy." No strength is given in the text used here.
The Twyneo label (a cream containing 0.1% tretinoin and 3% benzoyl peroxide, per its title) describes it as a combination tretinoin, a retinoid, and benzoyl peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.
What the sources say about regulatory status
The retinol trials, the benzoyl peroxide and network meta-analysis reviews, and the guideline abstract do not state a regulatory status for the products they studied or named. This guide therefore does not describe the status of retinol or adapalene products. The Tazorac and Twyneo sources are drug labels on DailyMed. The Twyneo label states an indication and the Tazorac label states a pregnancy contraindication, as quoted above. The text used here gives no approval date or approval status for either label.
Oral isotretinoin is separate from topical products
Oral isotretinoin is a different kind of treatment from the topical products above. The guideline abstract says oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy.
The Amnesteem (oral isotretinoin) label highlights say: "Amnesteem can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking Amnesteem in any amount, even for short periods of time." The text used here gives no approval date or approval status for the Amnesteem label.
What this does not tell you
This guide does not rank these options or say which suits a person. Each finding belongs to its own strengths, formulations, length and measures, and several strengths are not stated. A conclusion of parity or "little to no difference" is not a statement that two products are the same.
None of these sources describes a compounded cream. FDA says "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." A licensed provider decides which option, if any, is suitable.